Litcius/Paper detail

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors

Yue Zhou, Bo Wang, Jinghan Qu, Fan Yu, Yang Zhao, Shuyan Li, Ya Zeng, Xi Yang, Li Chu, Xiao Chu, Yida Li, Liqing Zou, Tiantian Guo, Luxi Ye, Fei Liang, Shengping Wang, Quan Liu, Jianjiao Ni, Zhengfei Zhu

2020Lung Cancer32 citationsDOI

Topics & Concepts

MedicineOsimertinibLung cancerMetastasisTyrosine kinaseCentral nervous systemOncologyBrain metastasisCancer researchInternal medicineCancerEpidermal growth factor receptorErlotinibReceptorLung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Research Studies
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors | Litcius